Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Open Access
- 26 February 2009
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 11 (3), 292-298
- https://doi.org/10.1093/eurjhf/hfp001
Abstract
Aims Chronic obstructive pulmonary disease is an independent predictor of mortality in patients with myocardial infarction (MI). However, the impact on mode of death and risk of atherosclerotic events is unknown. Methods and results We assessed the risk of death and major cardiovascular (CV) events associated with chronic obstructive pulmonary disease in 14 703 patients with acute MI enrolled in the Valsartan in Acute Myocardial Infarction (VALIANT) trial. Cox proportional hazards models were used to evaluate the relationship between chronic obstructive pulmonary disease and CV outcomes. A total of 1258 (8.6%) patients had chronic obstructive pulmonary disease. Over a median follow‐up period of 24.7 months, all‐cause mortality was 30% in patients with chronic obstructive pulmonary disease, compared with 19% in those without. The adjusted hazard ratio (HR) for mortality was 1.14 (95% confidence interval 1.02–1.28). This reflected increased incidence of both non‐CV death [HR 1.86 (1.43–2.42)] and sudden death [HR 1.26 (1.03–1.53)]. The unadjusted risk of all pre‐specified CV outcomes was increased. However, after multivariate adjustment, chronic obstructive pulmonary disease was not an independent predictor of atherosclerotic events [MI or stroke: HR 0.98 (0.77–1.23)]. Mortality was significantly lower in patients receiving beta‐blockers, irrespective of airway disease. Conclusion In high‐risk patients with acute MI, chronic obstructive pulmonary disease is associated with increased mortality and non‐fatal clinical events (both CV and non‐CV). However, patients with chronic obstructive pulmonary disease did not experience a higher rate of atherosclerotic events.Keywords
This publication has 35 references indexed in Scilit:
- Chronic obstructive pulmonary disease in patients admitted with heart failureJournal of Internal Medicine, 2008
- Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure TrialJournal of Cardiac Failure, 2007
- From COPD to chronic systemic inflammatory syndrome?The Lancet, 2007
- International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence studyThe Lancet, 2007
- Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint CommitteeThorax, 2007
- Impact of Chronic Obstructive Pulmonary Disease on Post-Myocardial Infarction OutcomesThe American Journal of Cardiology, 2007
- Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Patients Undergoing Percutaneous Coronary InterventionThe American Journal of Cardiology, 2005
- Inhaled ??2-Adrenoceptor AgonistsDrugs, 2005
- Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary interventionThe American Journal of Cardiology, 2004
- Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled β-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic DysfunctionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003